Drug intelligence / Profile preview

LBS-002

Development stage: Preclinical
Lead developer: Lin BioScience
Modality: Small Molecules

Overview

LBS-002 is a small molecule drug developed as a tubulin inhibitor, designed to disrupt the division of cancer cells by preventing the formation of microtubules. It is notable for its ability to cross the blood–brain barrier, making it a promising candidate for treating brain cancers such as glioblastoma and brain metastases, where traditional treatments are often ineffective due to poor permeability. The drug was initially developed by Lin BioScience in collaboration with researchers at the University of Sydney[1][2][3].

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on LBS-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBS-002.

Explore the full profile